Structural Heart Imaging Market
The structural heart imaging (SHI) market was valued at €15.9B in 2021 (TAM) and is set to grow at 10.6% CAGR reaching €29.85B in 2027. Higher prevalence of various congenital/cardiac diseases and poor lifestyle choices from the population that derivate to different health related problems (i.e., obesity, diabetes, or high pressure) are the main factors of the growth of the market. The VCG will create a new market niche which can be compared to the echocardiographic market. This market was valued at €1.38B (SAM) in 2020 and expects to reach €2.32B in 2030 growing at a 6% CAGR. Our company will firstly target the Europe Big 5 countries (France, Germany, Italy, Spain, and the UK) which market size is valued at €2.3B, growing at a CAGR of 10%. Lastly, J.E.M Tech is expected to generate €35M in revenues in 2029 (SOM) by expanding to the rest of the EU, USA and APAC countries.
Our targeted customers are hospitals with cardiac departments. There are more than 10.000 hospitals in Europe with this type of
department. Due to the rising elderly population worldwide, urbanization and poor lifestyle choices, it is predicted a 15% increase in
the next 10 years in cardiology hospitals in Europe alone. To reach this customers, JEM Tech has established networks and started
preliminary negotiations with potential distributors such as Sanitex S.r.l for the north of Italy and our consultant for distribution
network, Saverio laquinta. Our targeted end-users are cardiac surgeons. In Europe, the are 80.000 cardiology professionals that will
be able to use the VCG for the surgeries they perform. In addition, the beneficiaries of our product will be patients undergoing
open-chest surgeries. Roughly, around 1M of these surgeries is performed each year worldwide, the most common one is CABG
Cardiac mechanical behaviour is yet to be widely explored, therefore, the solutions are very limited. Most solutions available (magnetic resonance, x-rays, transesophageal echocardiography) are invasive, not intended to be used in operating rooms, expensive and providing mainly qualitative information of the heart. As doctors do not have access to quantitative information of the heart in real-time, it can lead to clinical
misjudgements that can worsen patients ‘outcomes. JEM Tech`s VCG opens a new segment of heart evaluation through a non-invasive solution, intended to be used in operating rooms and that provide semi-real time information of the patient`s heart
during the procedure, therefore, improving the patient`s outcome. The VCG is not intended to replace any of these solutions but to complement them and provide additional information that is currently missing to cardiac surgeons, eliminating human errors and therefore, improving the outcome of open-chest surgeries.